Cam Gallagher - 30 May 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role: President, Director
Signature: By: /s/ Melissa B. Epperly, Attorney-in-Fact for Cam S. Gallagher
Issuer symbol: ZNTL
Transactions as of: 30 May 2022
Net transactions value: $0
Form type: 4
Filing time: 31 May 2022, 16:06:08 UTC
Previous filing: 05 Apr 2022
Next filing: 15 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZNTL	Common Stock	Award	$0	+111,072	+31%	$0.000000	466,885	30 May 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZNTL	Stock Option (Right to Buy)	Award	$0	+333,218		$0.000000	333,218	30 May 2022	Common Stock	333,218	$24.75	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
F2	The options vest and become exercisable as to 25% of the total number of shares underlying the option on May 30, 2023 and as to the remaining 75% in 36 substantially equal monthly installments thereafter.